Download - Presentation ท่าหลวง260656
![Page 1: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/1.jpg)
![Page 2: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/2.jpg)
Background
Diabetes is one of the major causes of premature illness
and death worldwide.*
2010 global prevalence of
diabetes 6.4 %
2030 global prevalence of
diabetes 7.8 %*
*Reference : World Health Organization
![Page 3: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/3.jpg)
1998 Thai prevalence of
diabetes 4.7% *
2009 Thai prevalence of
diabetes 6.9% *
Reference : Thai national health survey 1998
Background
![Page 4: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/4.jpg)
Complication of Diabetes
Reference *http://www.medscape.org/viewarticle/449657
![Page 5: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/5.jpg)
Diabetic Nephropathy
Reference *http://www.medscape.org/viewarticle/449657
![Page 6: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/6.jpg)
The goal of treatment for chronic
kidney disease is to prevent or slow
further damage
![Page 7: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/7.jpg)
Literature review
Impact of Glycemic control on survival of diabetic
patients on chronic regular hemodialysis
Inoue
Hemodialysis
HbA1C
* Reference:Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, Shoji T, Nishizawa Y. :Impact of glycemic control
on survival of diabetic patients on chronic regular hemodialysis:7 year observational study. Division of Metabolism,
Endocrinology, and Molecular medicine, Department of Internal Medicine, Osaka city university Graduate medical school,1-4-
3, Asahi-machi Osaka, Japan 545-8585
![Page 8: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/8.jpg)
Literature review
Glycated protein as indices of glycemic control
in diabetic patient with chronic renal failure
HbA1c, fructosamine albumin adjusted fructosamine
mean capillary blood glucose concentration HbA1C
mean capillary blood glucose concentration
*Reference: Morgan. L, Marenah, C.B., Jeffcoate, W.J. and Morgan, A.G.,Glycated proteins as indices of Glyceamic
control in Diabetic patients with Chronic renal failure.Diabet.Med,13:514-519
![Page 9: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/9.jpg)
Literature review
• The unrecognized prevalence of chronic kidney
disease in diabetes
serum creatinine albuminuria estimated
glomerular eGFR
• *Reference: [5] Wild S, Roglic G, Green A,Sicree R,King H:Global prevalence of diabetes:estimates for the year 2000
• and projections for 2030.Diabetes Care27:1047-1053,2004
![Page 10: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/10.jpg)
“
*Reference : American Diabetes Association. Standards of Medical Care in Diabetes—2013. Alexandria, VA, American Diabetes Association, 2013
![Page 11: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/11.jpg)
![Page 12: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/12.jpg)
Conceptual Framework
DiabetesDiabetes with
nephropathyCKD
Stage5
(ESRD)
Stage1
Stage4
Stage3
Stage2
Tertiary Prevention
-Age
-Gender
-Race
-Behavior
-Medication
-BMI
-Blood pressure
-Glycemic control
-Lipid profile
![Page 13: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/13.jpg)
Objectives
–
–
–
![Page 14: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/14.jpg)
Study design
• Retrospective cohort study
– 3-21 2556
–
–
Duration
Study area
Outcome measurement
![Page 15: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/15.jpg)
Population
Study population )
2- 25542555 2556
( Target population )
( Population )
![Page 16: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/16.jpg)
Study population
–
2
2553 2556
– Creatinine 2556
– Creatinine -
2554
Inclusion criteria
Exclusion criteria
![Page 17: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/17.jpg)
Sampling
Estimating population proportion and adjusted framework
•
40%
n = (NZ2α/2 P Q ) / d2(N-1) + Z2
α/2 P Q
![Page 18: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/18.jpg)
Methods
1.
2.
3.
![Page 19: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/19.jpg)
Methods
4.
5.
6.
1.Gender
2. Age
3. BMI
4.U/D; HT, DLP
5.FBS
6.HbA1c
7.eGFR
8.Smorking
9.Alcohol drinking
10. Medication
![Page 20: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/20.jpg)
Time schedule
3 2556
•
72556
•
10 2556
•
•
![Page 21: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/21.jpg)
14-20 2556
• inclusion exclusion criteria
•
262556
•
![Page 22: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/22.jpg)
Result
Demographic Data
Glycemic Control
Correlations
![Page 23: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/23.jpg)
Demographic Data
Mean SD (Min-
Max) 58 11 (23-82)
35 22.7
119 77.3
7 4.5
138 89.6
1 0.6
8 5.2
4 2.6
![Page 24: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/24.jpg)
72 46.8
5 3.2
60 39.0
1 .6
2 1.3
14 9.1
Mean SD
(Min-Max)
63 14 (36-
101)
Mean SD
(Min-Max)
155 8
(135-175)
![Page 25: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/25.jpg)
135 87.7
11 7.1
8 5.2
134 87.0
![Page 26: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/26.jpg)
42 27.3
112 72.7
Cholesterol
≤200 mg/dl 114 74
>200 mg/dl 40 26
LDL
≤100mg/dl 79 51.3
>100mg/dl 75 48.7
HDL
≤40m
g/dl 32 20.8
>40m
g/dl 122 79.2
Triglyceride
≤150mg/dl 101 65.6
![Page 27: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/27.jpg)
Glycemic control
FBS):Mean SD (Min-Max)
137 25.5
(88-216)
FBS)
≤130mg/dl 74 48.1
>130mg/dl 80 51.9
HbA1C):Mean SD (Min-Max)
7.9 1.3(4.9
-11.2)
HbA1C)
≤6.5
% 24 15.6
>6.5
![Page 28: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/28.jpg)
GFR):Mean SD (Min-Max)
6.4 3.6(0.3
1-24.82)
GFR)
≤6.5
ml/min/m2/y
ear 74 48.1
>6.5
ml/min/m2/y
ear 80 51.9
2
31 20.1
3
121 78.6
1 .6
![Page 29: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/29.jpg)
Metfor
min
17 11.0
137 89.0
Glipizid
e
110 71.4
44 28.6
Glibenclamid
e
62 40.3
92 59.7
Insulin
![Page 30: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/30.jpg)
Correlation
GFR)
≤6.5 >6.5 OR
95%
Confidence
Interval
P-
VALU
E
FBS) 1.16
2
0.617-
2.189 0.642
≤130 37(50
)
37(5
0)
>130 37(46
.25)
43(5
3.75)
HbA1C) 2.48
0.993-
6.208 0.047
16(66 8(33.
![Page 31: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/31.jpg)
GFR)
≤6.5 >6.5 OR
95%
Confiden
ce
Interval
P-
VALU
E
Metformin 0.95
6
0.348-
2.624 0.931
8(47.06) 9(52.9
4)
66(48.18) 71(51.
82)
Glipizide
0.41
1
0.200-
0.845 0.014
46(41.82)
64(58.
18)
16(36.
![Page 32: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/32.jpg)
GFR)
≤6.5 >6.5 OR
95%
Confiden
ce
Interval
P-
VALU
E
Glipizide 2.43
0.200-
0.845 0.014
28(63.64)
16(36.
36)
46(41.82)
64(58.
18)
![Page 33: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/33.jpg)
Discussion
• (SD)6.4(3.6)
ml/min/m2/year
(SD) 3.8 ( 4.2) 4.0( 3.1)
ml/min/year
•
6.5%
6.5 ml/min/m2/year 2.48
![Page 34: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/34.jpg)
Discussion
•
, ,
Glycemic control Is a predictor of survival
for Diabetic Patients on Hemodialysis
• Glipizide
Use of insulin and oral hypoglycemic
medications in patients with diabetes mellitus and advanced
kidney disease
![Page 35: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/35.jpg)
Limitation• HbA1c
Anemia Hemoglobinopathies
• 2
• 3. 2553
• 4.
![Page 36: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/36.jpg)
Reccomentation
• 1.
• 2
![Page 37: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/37.jpg)
Acknowledgement
•
•
•
•
•
•
•
•
•
•
•
![Page 38: Presentation ท่าหลวง260656](https://reader033.vdocuments.pub/reader033/viewer/2022042816/559a382e1a28ab98158b475d/html5/thumbnails/38.jpg)